BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Morino Y, Sugimoto M, Nagata N, Niikiura R, Iwata E, Hamada M, Kawai Y, Fujimiya T, Takeuchi H, Unezaki S, Kawai T. Influence of Cytochrome P450 2C19 Genotype on Helicobacter pylori Proton Pump Inhibitor-Amoxicillin-Clarithromycin Eradication Therapy: A Meta-Analysis. Front Pharmacol 2021;12:759249. [PMID: 34721043 DOI: 10.3389/fphar.2021.759249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Kuang W, Zhang H, Wang X, Yang P. Overcoming Mycobacterium tuberculosis through small molecule inhibitors to break down cell wall synthesis. Acta Pharmaceutica Sinica B 2022. [DOI: 10.1016/j.apsb.2022.04.014] [Reference Citation Analysis]
2 Graham DY, Hernaez R, Rokkas T. Cross-roads for meta-analysis and network meta-analysis of H. pylori therapy. Gut 2021:gutjnl-2021-326170. [PMID: 34750206 DOI: 10.1136/gutjnl-2021-326170] [Reference Citation Analysis]
3 Maev IV, Mkrtumyan AM, Bektemirova LG, Andreev DN, Dicheva DT. The effectiveness of eradication therapy of the 1st line of Helicobacter pylori infection in patients with type 2 diabetes mellitus. Terapevticheskii arkhiv 2022;94:209-15. [DOI: 10.26442/00403660.2022.02.201372] [Reference Citation Analysis]